Skip to Content

Manning & Napier Overseas Series I EXOSX

Medalist Rating as of | See Manning & Napier Advisors Inc. Investment Hub
  • NAV / 1-Day Return 31.38  /  −0.10 %
  • Total Assets 647.7 Mil
  • Adj. Expense Ratio
    0.750%
  • Expense Ratio 0.750%
  • Distribution Fee Level Below Average
  • Share Class Type Institutional
  • Category Foreign Large Growth
  • Investment Style Large Growth
  • Min. Initial Investment 1.0 Mil
  • Status Open
  • TTM Yield 1.29%
  • Turnover 49%

USD | NAV as of Feb 24, 2024 | 1-Day Return as of Feb 24, 2024, 1:24 AM GMT+0

Morningstar’s Analysis EXOSX

Will EXOSX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Manning& Napier Overseas Series I’s management team is rated Average, but a solid investment process still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a sizable cost advantage over competitors, priced within the second-cheapest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings EXOSX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 38.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

AstraZeneca PLC ADR

5.03 32.0 Mil
Healthcare

Taiwan Semiconductor Manufacturing Co Ltd ADR

4.78 30.4 Mil
Technology

Nestle SA

4.05 25.8 Mil
Consumer Defensive

Samsung Electronics Co Ltd

3.88 24.7 Mil
Technology

Dreyfus Government Cash Mgmt Instl

3.60 22.9 Mil
Cash and Equivalents

Unilever PLC ADR

3.58 22.8 Mil
Consumer Defensive

Deutsche Boerse AG

3.58 22.8 Mil
Financial Services

BAE Systems PLC

3.54 22.5 Mil
Industrials

Heineken NV

3.53 22.5 Mil
Consumer Defensive

Novartis AG ADR

3.51 22.3 Mil
Healthcare